ClusterVAP : study protocol for multicentre proteomic endotyping of ventilator-associated pneumonia
(2026) In BMJ Open Respiratory Research 13(1).- Abstract
INTRODUCTION: Ventilator-associated pneumonia (VAP) is the most frequent healthcare-associated infection in intensive care units and is associated with high morbidity and mortality. Current diagnostic criteria lack specificity, leading to misclassification and unnecessary antibiotic use. Identifying patient subgroups with a common pathophysiological basis (pneumoclusters) may distinguish true VAP of varying aetiology and severity from non-infectious mimics, enabling more targeted therapy and improved antimicrobial stewardship.
METHODS AND ANALYSIS: ClusterVAP is an exploratory, observational, prospective, multicentre cross-sectional study conducted in intensive care units across Sweden, France, Portugal, Denmark and the UK.... (More)
INTRODUCTION: Ventilator-associated pneumonia (VAP) is the most frequent healthcare-associated infection in intensive care units and is associated with high morbidity and mortality. Current diagnostic criteria lack specificity, leading to misclassification and unnecessary antibiotic use. Identifying patient subgroups with a common pathophysiological basis (pneumoclusters) may distinguish true VAP of varying aetiology and severity from non-infectious mimics, enabling more targeted therapy and improved antimicrobial stewardship.
METHODS AND ANALYSIS: ClusterVAP is an exploratory, observational, prospective, multicentre cross-sectional study conducted in intensive care units across Sweden, France, Portugal, Denmark and the UK. Mechanically ventilated patients aged 18 years or older with newly developed clinical signs of lower respiratory tract infection will undergo bronchoalveolar lavage (BAL) or mini BAL sampling on clinical indication. Proteomic profiling using liquid chromatography tandem mass spectrometry will be performed on BAL supernatants. Unsupervised consensus clustering will define pneumoclusters, which will be characterised using clinical, microbiological and radiological data. 30-day outcomes, including mortality, ventilator-free days, antibiotic-free days, intensive care unit-free days and hospital-free days, will be compared across clusters to describe clinical trajectories. Candidate protein biomarkers for pragmatic cluster assignment will be derived using differential expression analysis.
ETHICS AND DISSEMINATION: Ethical approval will be obtained at all participating sites. Deferred consent will be used where permitted, with subsequent patient or proxy consent according to local regulations. Results will be disseminated through peer-reviewed publications and scientific conferences.
TRIAL REGISTRATION NUMBER: NCT07245888.
(Less)
- author
- Sjövall, Fredrik
LU
; Póvoa, Pedro
; Petersson, Johan
; Koulenti, Despoina
; Hernandez Padilla, Ana Catalina
; Vaidie, Julien
; Lind, Alicia
; Boëtius Hertz, Frederik
and Paulsson, Magnus
LU
- organization
- publishing date
- 2026-03-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Humans, Pneumonia, Ventilator-Associated/diagnosis, Proteomics/methods, Prospective Studies, Cross-Sectional Studies, Intensive Care Units, Multicenter Studies as Topic, Bronchoalveolar Lavage Fluid/chemistry, Biomarkers/analysis, Male, Bronchoalveolar Lavage, France, Female, Respiration, Artificial/adverse effects, Observational Studies as Topic
- in
- BMJ Open Respiratory Research
- volume
- 13
- issue
- 1
- article number
- e003830
- pages
- 5 pages
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:41802817
- ISSN
- 2052-4439
- DOI
- 10.1136/bmjresp-2025-003830
- language
- English
- LU publication?
- yes
- additional info
- © Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY. Published by BMJ Group.
- id
- a1075f2c-d1ce-4df6-b278-9d432491705c
- date added to LUP
- 2026-03-10 08:13:08
- date last changed
- 2026-03-10 10:08:37
@article{a1075f2c-d1ce-4df6-b278-9d432491705c,
abstract = {{<p>INTRODUCTION: Ventilator-associated pneumonia (VAP) is the most frequent healthcare-associated infection in intensive care units and is associated with high morbidity and mortality. Current diagnostic criteria lack specificity, leading to misclassification and unnecessary antibiotic use. Identifying patient subgroups with a common pathophysiological basis (pneumoclusters) may distinguish true VAP of varying aetiology and severity from non-infectious mimics, enabling more targeted therapy and improved antimicrobial stewardship.</p><p>METHODS AND ANALYSIS: ClusterVAP is an exploratory, observational, prospective, multicentre cross-sectional study conducted in intensive care units across Sweden, France, Portugal, Denmark and the UK. Mechanically ventilated patients aged 18 years or older with newly developed clinical signs of lower respiratory tract infection will undergo bronchoalveolar lavage (BAL) or mini BAL sampling on clinical indication. Proteomic profiling using liquid chromatography tandem mass spectrometry will be performed on BAL supernatants. Unsupervised consensus clustering will define pneumoclusters, which will be characterised using clinical, microbiological and radiological data. 30-day outcomes, including mortality, ventilator-free days, antibiotic-free days, intensive care unit-free days and hospital-free days, will be compared across clusters to describe clinical trajectories. Candidate protein biomarkers for pragmatic cluster assignment will be derived using differential expression analysis.</p><p>ETHICS AND DISSEMINATION: Ethical approval will be obtained at all participating sites. Deferred consent will be used where permitted, with subsequent patient or proxy consent according to local regulations. Results will be disseminated through peer-reviewed publications and scientific conferences.</p><p>TRIAL REGISTRATION NUMBER: NCT07245888.</p>}},
author = {{Sjövall, Fredrik and Póvoa, Pedro and Petersson, Johan and Koulenti, Despoina and Hernandez Padilla, Ana Catalina and Vaidie, Julien and Lind, Alicia and Boëtius Hertz, Frederik and Paulsson, Magnus}},
issn = {{2052-4439}},
keywords = {{Humans; Pneumonia, Ventilator-Associated/diagnosis; Proteomics/methods; Prospective Studies; Cross-Sectional Studies; Intensive Care Units; Multicenter Studies as Topic; Bronchoalveolar Lavage Fluid/chemistry; Biomarkers/analysis; Male; Bronchoalveolar Lavage; France; Female; Respiration, Artificial/adverse effects; Observational Studies as Topic}},
language = {{eng}},
month = {{03}},
number = {{1}},
publisher = {{BMJ Publishing Group}},
series = {{BMJ Open Respiratory Research}},
title = {{ClusterVAP : study protocol for multicentre proteomic endotyping of ventilator-associated pneumonia}},
url = {{http://dx.doi.org/10.1136/bmjresp-2025-003830}},
doi = {{10.1136/bmjresp-2025-003830}},
volume = {{13}},
year = {{2026}},
}